Radiotherapy omission in low-risk hormone receptor–positive breast cancer: insights from a Korean single-center cohort Authors: Haeyoung Kim Published: 2025 Breast-conserving surgery (BCS) followed by radiotherapy has long represented the standard of care for early-stage breast cancer, supported by randomized trials and meta-analyses that have demonstrated substantial reductions in ipsilateral breast tumor recurrence and modest improvements in breast cancer mortality [1,2]. As our understanding of tumor biology has evolved and endocrine therapy has become more widely adopted, interest has grown in identifying subsets of patients with truly low-risk, hormone receptor (HR)–positive disease for whom postoperative radiotherapy might be omitted. However, despite decades of research, no clinicopathological subgroup has been conclusively demonstrated to achieve a sufficiently low recurrence risk to omit the local control benefit of radiotherapy. Evidence from the Early Breast Cancer Trialists’ Collaborative Group meta-analysis, the NSABP B-21 trial, CALGB 9343, and PRIME II consistently demonstrated that even among patients considered lowest risk, omitting radiotherapy is associated with increased local recurrence than with radiotherapy [1-4]. Accordingly, although treatment de-escalation is an important goal, radiotherapy omissions continue to require thoughtful consideration. In this issue of Radiation Oncology Journal, Song et al. [5] presented an important early Korean report evaluating radiotherapy omission in a narrowly selected, low-risk cohort. Using their single-center hospital’s database, the investigators identified postmenopausal women with pT1N0/Nx, grade 1–2, HR-positive/human epidermal growth factor receptor 2–negative tumors and Ki-67 ≤20% who underwent BCS and endocrine therapy. Among the 742 eligible patients treated between 2010 and 2020, 707 received radiotherapy and 35 did not. With a median follow-up of less than 6 years in the omission group, no locoregional recurrences were observed, and the overall recurrence rates remained low in both cohorts after propensity score matching. These findings suggest that within highly structured clinical settings, radiotherapy omission may be feasible for a very small, stringently selected subset of patients with biologically favorable disease. In Song et al.’s cohort [5], routine preoperative magnetic resonance imaging, strict clinicopathologic selection, and high adherence to endocrine therapy likely contributed to excellent outcomes, despite omitting radiotherapy. Despite these favorable outcomes, caution should be exercised. This study was conducted at a single tertiary institution, which limits its generalizability across diverse clinical environments. The retrospective design also introduced selection bias that could not be fully eliminated, as radiotherapy decisions are influenced by age, comorbidity, and physician judgment. Another important limitation was the small number of patients who did not receive radiotherapy (n = 35). Although no recurrences were observed, the omission cohort was too small to draw firm conclusions, and the absence of events in such a limited sample cannot be interpreted as evidence of long-term safety. The relatively short follow-up period warrants further consideration. HR-positive breast cancer is characterized by a sustained risk of late recurrence that extends well beyond 10–15 years [6]. Differences in local recurrence between radiotherapy and no radiotherapy often become more evident with extended observation [2]. These features underscore the need for long-term follow-ups when evaluating the safety of radiotherapy omissions. Another important factor to consider is that all patients in Song et al.’s cohort [5] initiated endocrine therapy and most completed the planned 5-year course. However, in routine practice, adherence tends to be lower. Large population-based studies have reported discontinuation or nonadherence rates approaching 40%–50% within 5 years, with poorer adherence associated with increased recurrence and mortality [7]. Thus, when considering radiotherapy omission, clinicians should recognize that the excellent outcomes reported by Song et al. [5] may not be reproducible in settings with lower endocrine therapy adherence, and should incorporate this into individualized decision-making. The Korean healthcare system influences the clinical applicability of radiotherapy omission. Radiotherapy is widely accessible in Korea and is associated with low out-of-pocket costs owing to national health insurance coverage. Additionally, nationwide practice trends have shown a rapid increase in partial breast irradiation and hypo-fractionated or ultra-hypofractionated schedules, with hypofractionation increasing from approximately one-third of breast radiotherapy in 2017 to nearly 90% in 2022 [8]. Importantly, radiotherapy substantially reduces the risk of locoregional recurrence, thereby lowering the likelihood of salvage mastectomy or other reinterventions. These features of treatments in Korea—and the availability of contemporary 1–2-week regimens—are important considerations when assessing whether radiotherapy omission is genuinely warranted for Korean patients with low-risk HR-positive breast cancer. The growing interest in biologically guided de-escalation reflects the recognition that clinicopathological features alone may not adequately capture the recurrence risk. Early studies such as LUMINA and IDEA are encouraging but remain limited by single-arm designs and relatively short follow-up periods [9,10]. Ongoing trials including PRIMETIME, EXPERT, DEBRA, and PRECISION are testing similar strategies in broader prospective settings. Long-term data are ultimately needed to determine whether biological selection can reliably support the omission of radiotherapy. Taken together, the findings of Song et al. [5] provide an early Korean insight suggesting that radiotherapy omission may be feasible in carefully selected postmenopausal women with favorable HR-positive disease. However, the single-center design, retrospective nature, small cohort, and relatively short follow-up period underscore the need for caution. Further multicenter Korean studies with long-term follow-up and the integration of molecular profiling are crucial to determine when radiotherapy can be safely omitted.